<DOC>
	<DOCNO>NCT03064347</DOCNO>
	<brief_summary>This study evaluate whether enteric-coated nutrient increase glucose regulate hormone level , glucose tolerance satiety overweight obese individual type 2 diabetes .</brief_summary>
	<brief_title>Targeted Enteral Nutrient Delivery : A Prospective Randomized Study</brief_title>
	<detailed_description>Direct delivery nutrient upper intestine enteral feeding tube increase circulating level glucose appetite regulating hormone compare usual oral ingestion . Such enhancement could value management type 2 diabetes obesity . In study enteric-coated nutrient ingest allow direct delivery nutrient upper intestine . Levels select hormone glucose , measure satiety adverse effect compare follow ingestion uncoated enteric coated nutrient .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1865 year age BMI &gt; 27kg/m2 Type 2 diabetes know duration &lt; 10years On metformin , sulfonylurea , thiazolidinedione SGLT2 inhibitor lifestyle management alone combination management type 2 diabetes Conditions Known foregut pathology prior foregut surgery . Previous surgical treatment obesity ( exclude liposuction perform &gt; one year trial entry ) Known cardiovascular disease control hypertension Known proliferative retinopathy maculopathy require acute treatment , judge Investigator Known untreated uncontrolled hypothyroidism/hyperthyroidism History chronic pancreatitis idiopathic acute pancreatitis Obesity induce endocrinologic disorder ( e.g . Cushing Syndrome ) Cancer ( past present except basal cell skin cancer squamous cell skin cancer ) , Investigator 's opinion could interfere result trial Use insulin , DPP4 inhibitor GLP1 analogs previous 1 month Treatment antidiabetic agent ( ) metformin , sulphonylurea thiazolidinedione SGLT2 inhibitor 1 month prior screen Use drug ( except metformin , sulphonylurea thiazolidinedione SGLT2 inhibitor ) , Investigator 's opinion could interfere glucose level ( e.g . systemic corticosteroid ) Receipt antidiabetic investigational drug within 1 month prior screen trial , receipt investigational drug affect diabetes within 1 month prior screen trial Current history treatment medication may cause significant weight gain , within 1 month prior screen trial , include systemic corticosteroid ( except short course treatment , i.e. , 7 10 day ) , tricyclic antidepressant , atypical antipsychotic mood stabilizer ( e.g. , imipramine , amitryptiline , mirtazapin , paroxetine , phenelzine , clorpromazine , olanzapine , valproic acid derivative , lithium ) thioridazine , clozapine , Currently use use within three month prior screen trial : pramlintide , sibutramine , orlistat , zonisamide , topiramate phenteremine ( either prescription part clinical trial ) Simultaneous participation clinical trial investigational drug The receipt investigational product within four week prior screen trial Herbal supplement overthecounter medication Diet attempt use herbal supplement overthecounter medication within 1 month prior screen trial Other Milk allergy Lactose intolerance Language barrier , mental incapacity , unwillingness inability understand able complete study Females childbearing potential Pregnant breastfeed intend become pregnant use adequate contraceptive method ( adequate contraceptive measure require US : abstinence follow method : diaphragm spermacide , condom spermacide ( male partner ) , intrauterine device , sponge , spermacide , Norplant® , DepoProvera® oral contraceptive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Obesity</keyword>
	<keyword>Nutrient</keyword>
</DOC>